SynopsisNelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. The global Nelarabine market was valued at US$ 134 million in 2023 and is anticipated to reach US$ 146.3 million by 2030, witnessing a CAGR of 1.1% during the forecast period .....
SynopsisArranon is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. The global Arranon market was valued at US$ 79 million in 2023 and is anticipated to reach US$ 85 million by 2030, witnessing a CAGR of 1.2% during the forecast period 2024-2030......
SynopsisAtriance is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. The global Atriance market was valued at US$ 56 million in 2023 and is anticipated to reach US$ 62 million by 2030, witnessing a CAGR of 1.1% during the forecast period 2024-203.....
SynopsisInotuzumab ozogamicin is an antibody-drug conjugate used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The global Inotuzumab Ozogamicin market was valued at US$ 219 million in 2023 and is anticipated to reach US$ 40.....
SynopsisBesponsa is an antibody-drug conjugate used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The global Besponsa market was valued at US$ 219 million in 2023 and is anticipated to reach US$ 405.9 million by 2030, witne.....
SynopsisEnasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test The global Enasidenib market wa.....
SynopsisEnasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test The global Enasidenib Drugs mar.....
SynopsisIdhifa is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test The global Idhifa market was valued.....
SynopsisGemtuzumab ozogamicin is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myeloid leukemia from 2000 to 2010. The global Gemtuzumab Ozogamicin market was valued at US$ 214.3 million in 2023 and is anticipated to.....
SynopsisGemtuzumab ozogamicin is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myeloid leukemia from 2000 to 2010. The global Gemtuzumab Ozogamicin Drugs market was valued at US$ 214.3 million in 2023 and is anticipa.....
